1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Cassiopea Wins With Winlevi Acne Phase III Data

 
• By Kevin Grogan

The Italian-headquartered, Swiss-listed company spun out of Cosmo Pharmaceuticals has moved a step closer to having the first topical anti-androgen drug approved for acne.

SC1807_Hiding Face_387608575_1200.jpg
Cassiopea Unveils Strong Data • Source: Shutterstock

Shares in Italy's Cassiopea SPA have soared on the back of impressive top-line late-stage data which suggests that Winlevi (clascoterone) could provide the first new mechanism for the treatment of acne for decades.

Cassiopea, which was spun out of Cosmo Pharmaceuticals NV as a pure-play dermatology company in 2015 and is listed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.